Noxopharm confirms NOX66 as non-toxic

Company News

by Jessica Amir

Noxopharm Limited (ASX:NOX) has received a green light to proceed with the recruitment of more patients for its anti-cancer drug, NOX66.

It comes as the cancer treatment company received clearance from its Data Safety Monitoring Committee that the drug was non-toxic.

The review of the first group of patients found that after 14 continuous days of NOX66, there were no untoward side-effects.

The trial is on patients with late-stage breast, lung, ovary, prostate and head and neck cancers, who stopped responding to chemotherapy.

The company has now started phase 1b of the combination treatment .

Shares in Noxopharm Limited (ASX:NOX) are trading 2.56 per cent lower to 38 cents.

Jessica Amir

Finance News Network
Jessica joined FNN in January 2017 after having worked in financial advising for seven years and in TV journalism for seven years, specialising in finance, equities and analysis. She has interviewed former Prime Ministers of Australia, Tony Abbott, Julia Gillard and Kevin Rudd and ex Treasurer Jo Hockey. Jessica has worked as a journalist with Sky News Business, ABC 1, ABC's The Business, ABC24 and has also been a regional Channel 7 and 9 TV reporter with Prime7 and Win News.